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A B S T R A C T
Background
Reduced intake and absorption of antioxidants due to pain and malabsorption are probable causes of the lower levels of antioxidants
observed in patients with chronic pancreatitis (CP). Improving the status of antioxidants might be effective in slowing the disease
process and reducing pain in CP.
Objectives
To assess the benefits and harms of antioxidants for the treatment of pain in patients with CP.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and the Conference Proceedings
Citation Index from inception to October 2012. Two review authors performed the selection of trials independently.
Selection criteria
We included all randomised controlled trials (RCTs) evaluating antioxidants for treatment of pain in CP. All trials were included
irrespective of blinding, numbers of participants randomly assigned and language of the article.
Data collection and analysis
Two review authors extracted data independently. The risk of bias of included trials was assessed. Study authors were asked for additional
information in the case of missing data.
Main results
Twelve RCTs with a total of 585 participants were included. Six trials were double-blinded, placebo-controlled studies, and the other
six trials were of less adequate methodology. Most trials were small and had high rates of dropout. Eleven of the 12 included trials
described the effects of antioxidants on chronic abdominal pain in chronic pancreatitis. Pain as measured on a visual analogue scale
(VAS, scale range 0 to 10) after one to six months was less in the antioxidant group than in the control group (mean difference (MD)
-0.33, 95% confidence interval (CI) -0.64 to -0.02, P value 0.04, moderate-quality evidence). The number of pain-free participants
was not statistically significantly different (risk ratio (RR) 1.73, 95% CI 0.95 to 3.15, P value 0.07, low-quality evidence). More
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adverse events were observed in the antioxidant group, both in the parallel trials (RR 4.43, 95% CI 1.60 to 12.29, P value 0.0004,
moderate-quality evidence) and in the cross-over trials (RR 5.80, 95% CI 1.56 to 21.53, P value 0.0009, moderate-quality evidence).
Adverse events occurred in 16% of participants and were mostly mild (e.g. headache, gastrointestinal complaints), but were sufficient
to make participants stop antioxidant use. Other important outcomes such as use of analgesics, exacerbation of pancreatitis and quality
of life were rarely reported. One trial from 1991 evaluated the effects of antioxidants on acute pain during exacerbation of chronic
pancreatitis and found that a significantly higher proportion of participants in the antioxidant group experienced pain relief. This trial
was conducted more than 25 years ago and has not been reproduced since that time. Therefore, additional trials are needed before
reliable conclusions can be drawn.
Authors’ conclusions
Current evidence shows that antioxidants can reduce pain slightly in patients with chronic pancreatitis. The clinical relevance of this
small reduction is uncertain, and more evidence is needed. Adverse events in one of six patients may prevent the use of antioxidants.
Effects of antioxidants on other outcome measures, such as use of analgesics, exacerbation of pancreatitis and quality of life remain
uncertain because reliable data are not available.
P L A I N L A N G U A G E S U M M A R Y
Antioxidants to reduce pain in chronic pancreatitis
Chronic pancreatitis is a persistent inflammation of the pancreas that in the long run can cause irreparable damage. The major causes of
chronic pancreatitis are genetics, alcohol toxicity and other conditions that might damage or obstruct the pancreas. This inflammation
can cause pain that often is severe and leaves patients socially isolated and unable to perform their jobs. Unfortunately, treatment
options are scarce, and often strong morphine-like pain medications are needed. Patients might benefit from alternative medication
without the adverse effects associated with morphine-like medication. This review summarises the evidence from randomised trials on
the effects of antioxidants in chronic pancreatitis. Antioxidants are substances that prevent damage to cells caused by toxic byproducts
of oxygen in the body. Levels of these byproducts are increased in chronic pancreatitis. Antioxidants constitute a large group that
contains many natural and man-made products. Examples include vitamin C, vitamin E, flavonoids (present in tea and cocoa) and
many specialised medications. We found 12 randomised trials on this topic. The quality of these trials was mixed, and many had small
sample sizes and high rates of dropout. Evidence shows that antioxidants may reduce pain in patients with chronic pancreatitis, but
the reported reduction in pain was small. Whether this small decrease really had an impact on patients’ complaints is not clear. Given
the methodological problems of these trials, a strong conclusion could not be drawn. Use of antioxidants resulted in adverse effects in
about 16% of study participants. Most adverse effects were mild, such as headache, nausea and constipation. However, participants
who developed these adverse effects tended to stop using antioxidant medication. Other outcomes important for decision making such
as use of analgesics, rate of exacerbation of pancreatitis and quality of life, were not very well reported. Therefore, we were unable to
reach conclusions on these outcomes.
2Antioxidants for pain in chronic pancreatitis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antioxidant versus control intervention for pain in chronic pancreatitis
Patient or population: pat ients with pain in chronic pancreat it is
Intervention: ant ioxidant versus control intervent ion
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* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI.
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a3 trials had high dropout rates. 1 trial also suf fered f rom select ive report ing of outcomes.
bAll t rials had high rates of dropout. 1 trial was not blinded, and another suf fered f rom select ive report ing.
cHeterogeneity was high between trials (I2 = 71%).























































































B A C K G R O U N D
Description of the condition
Chronic pancreatitis (CP) is an irreversible inflammatory pro-
cess of the pancreas, characterised by damage to the pancreas
parenchyme and loss of pancreatic function. The annual incidence
and prevalence are estimated at around seven and 20 per 100,000,
respectively (Dite 2001; Levy 2006; Spanier 2008). Development
of CP is probably due to a complex interrelationship of etiological
factors, of which the most important are alcohol toxicity, genetic
predisposition, duct obstruction, trauma, pancreas divisum and
autoimmune pancreatitis (Spanier 2008; Witt 2007).
Abdominal pain is the most prominent symptom in CP (van
Esch 2006; Witt 2007). Pain in CP can be severe, debilitating
and challenging to treat. Several options for treatment of pain are
known, including lifestyle recommendations, use of analgesics and
endoscopic or surgical intervention (Apte 1999; Gachago 2008).
Formany patients, however, these optionsmay be inappropriate or
may prove ineffective. Furthermore, long-standing disease results
in loss of pancreatic function. Exocrine insufficiency can lead to
steatorrhoea,malnutrition, abdominal discomfort andweight loss.
Endocrine insufficiency results in diabetes. CP thereby also leads to
substantial impairment in quality of life for most patients (Pezzilli
2005; Wehler 2004).
Description of the intervention
Antioxidant supplements have been suggested as potentially use-
ful treatment for pain in CP. Antioxidants are man-made and nat-
ural substances that can inhibit the production of free radicals
or can bind and inactivate them (Feng 2010). Examples of an-
tioxidants include vitamin C, vitamin A, vitamin E, glutathione,
flavonoids (in tea, cocoa and several fruits and vegetables), super-
oxide dismutase and various peroxidases. Free radicals are asso-
ciated with many deleterious effects as a result of their chemical
reactivity. Unbound, they can cause damage to all cellular macro-
molecules, including proteins, carbohydrates, lipids and nucleic
acids (Ramos-Márquez 2008). Epidemiological studies have re-
ported that antioxidants may have both anti-inflammatory and
anticarcinogenic effects (Owen 2000; Sala 2002). Furthermore,
some researchers suggest that intake of natural antioxidants re-
duces the risks of cancer, coronary heart disease, diabetes and
Alzheimer’s disease (Temple 2000; Willett 2002). In general, an-
tioxidants are associated with few (direct) adverse effects, espe-
cially when doses are low (e.g. comparable normal diet intake).
With high-dose supplementation, headaches and gastrointestinal
discomfort have been reported (Bhardwaj 2009; Bilton 1994a).
However, over the long term, not all reports on the use of antiox-
idants are positive; for example, a recent Cochrane review com-
paring antioxidants versus placebo found that long-term prophy-
lactic use of some antioxidants like beta carotene, vitamin A and
vitamin E may even increase mortality (Bjelakovic 2008). Other
antioxidants were not associatedwith this effect (Bjelakovic 2008).
Therefore, thorough evaluation is needed before antioxidants can
be implemented as standard of care.
How the intervention might work
Studies have shown that patients with CP have a significantly
lower level of circulating antioxidants and increased free radical
activity compared with healthy controls (Bowrey 1999; Guyan
1990; Kalvaria 1986). Reduced intake of antioxidants and post-
prandial pain along with reduced resorption due to malabsorption
caused by exocrine pancreatic insufficiency are probable causes of
decreased antioxidant status in patients with CP (Bhardwaj 2004;
Rose 1986). Improving the status of antioxidants might reduce
antioxidant stress and provide a way to ameliorate the disease pro-
cess while reducing pain in CP (Witt 2007).
Why it is important to do this review
No satisfactory treatment for pain in CP is available. Non-opioid
analgesics fail to relieve pain in many patients. Opioid analgesics
are associated with many complications, like somnolence, obstipa-
tion and nausea, and present a serious risk of dependency. Antiox-
idants could be a promising alternative treatment that may relieve
pain, improve health status and enhance quality of life in patients
with CP. In contrast, potential harms of antioxidants should be
thoroughly evaluated as well. This review aims to evaluate avail-
able evidence for both benefits and harms associated with the use
of antioxidants in patients with CP.
O B J E C T I V E S
To assess the benefits and harms of antioxidants for the treatment
of pain in patients with CP.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) evaluating antioxidants
for treatment of pain in CP. Trials were included irrespective of
blinding, numbers of participants randomly assigned or language
of publication. Quasi-randomised trials were excluded.
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Types of participants
We included all adult patients with establishedCP according to the
criteria of at least one international guideline (Schneider 2007).
Patients must have had some degree of pain, described as constant
pain or as recurrent pain attacks.
Types of interventions
Trials with any of the following comparisons were included with-
out restriction of dose, frequency, intensity, duration or route of
administration.
• Trials comparing any antioxidant regimen, single or
compound, versus placebo.
• Trials comparing different antioxidant regimens versus each
other.
• Trials comparing any antioxidant regimen versus any other
control intervention.
The following definitions for the different treatment modalities
were used.
• Antioxidant: any medicinal product that inhibits the
production of free radicals, or binds and inactivates them.
• Single antioxidant: use of only one antioxidant product
during the study period.
• Combination antioxidants: use of more than one
antioxidant product during the study period.
• Other control intervention: any substance or intervention
that may have a pharmacological effect and is used as a control.
Types of outcome measures
Primary outcomes
• Pain: pain complaints after the intervention compared with
before the intervention. Pain is a subjective outcome, and many
different ways of measuring pain are used; therefore, no strict
definition of pain can be provided. The pain outcome measures
used in all trials are presented in a matrix table (Table 1).
Secondary outcomes
• Mortality.
• Adverse effects, including nausea, constipation, allergic
reaction or any other as reported.. Adverse effects were classified
as minor (e.g. headache, gastrointestinal intolerance) and major
complications (e.g. allergic reactions).
• Pain medication: need for use of (additional) analgesic with
no restriction on type of analgesic used.
• Quality of life.
• Number of admissions and duration of hospital stay during
trial period.
• Number of pancreatitis events.
• Number of lost workdays.
• Antioxidant status measures: dependent on the antioxidant
marker reported by trial authors.
Search methods for identification of studies
Electronic searches
The following databases were searched.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Appendix 1).
• MEDLINE via OVID (from 1950 to present) (Appendix
2).
• EMBASE via OVID (from 1980 to present) (Appendix 3).
• Conference Proceedings Citation Index-Science (CPCI-S)
(from 1990 to present) (Appendix 4).
We developed these search strategies in cooperation with the
Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
(see Acknowledgements).
Searching other resources
A cross-reference searchwas performed of all included randomised
trials and relevant reviews identified during the search process.
Data collection and analysis
This review was conducted according to the recommendations
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2008).
Selection of studies
Titles and abstracts were screened by two review authors indepen-
dently. All potentially relevant hits were selected. In case of any
uncertainty, hits were selected as well. Selection based on full text
was performed by two review authors according to inclusion crite-
ria. Disagreements were resolved by discussion. Excluded studies
and reasons for exclusion are provided in the Characteristics of
excluded studies table.
Data extraction and management
Two review authors independently extracted all relevant data.
For each trial, participant characteristics, trial characteristics, data
needed for methodological quality assessment of the trial and pri-
mary and secondary outcome measures were extracted according
to availability. Data regarding participant characteristics included
number of participants in each group, age and gender of partici-
pants, duration and etiology of disease, alcohol use, smoking and
need for analgesic at baseline. Data regarding trial characteristics
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included study design, sample size calculation, inclusion and ex-
clusion criteria of the trial, follow-up period, loss to follow-up
and information regarding antioxidant supplements. The latter
included the type of antioxidant supplement used, the duration
of treatment and the timing of outcome assessment.
Assessment of risk of bias in included studies
Based on available empirical evidence and the recommendations
of the Cochrane Handbook for Systematic Reviews of Interventions,
we assessed the methodological quality of RCTs by using the tool
for assessing risk of bias (Higgins 2008; Kjaergard 2001; Moher
1998; Schulz 1995). The following definitions were used for items
assessed by this tool.
Sequence allocation
• Adequate: if the allocation sequence was generated by a
computer or a random number table. Drawing lots, tossing a
coin, shuffling cards and throwing dice were considered adequate
if a person who was not otherwise involved in the recruitment of
participants performed the procedure.
• Unclear: if the trial was described as randomised, but the
method used for generation of the allocation sequence was not
described.
• Inadequate: if a system involving dates, names or
alternating allocation was used for allocation of participants.
Allocation concealment
• Adequate; if allocation of participants involved a central
independent unit, an on-site locked computer or sealed
envelopes.
• Unclear: if the trial was described as randomised, but the
method used to conceal the allocation was not described.
• Inadequate: if the allocation sequence was known to the
investigators who assigned participants.
Blinding
• Adequate: if the trial was described (at least) as blind to
participants or assessors and the method of blinding was
described.
• Unclear: if the trial was described as (double) blind, but the
method of blinding was not described.
• Inadequate: if the trial was not blinded.
Incomplete data outcome
• Adequate: if the percentage of dropouts did not exceed
20%, and numbers of and reasons for dropouts and withdrawals
in all intervention groups are described.
• Unclear: if the report gives the impression that no dropouts
or withdrawals occurred, but this is not specifically stated.
• Inadequate: if the percentage of dropouts exceeds 20%, or
the numbers of and reasons for dropouts and withdrawals are not
described.
Selective outcome reporting
• Adequate: if it was clear that published reports include all
expected outcomes, including those that were prespecified.
• Unclear: if insufficient information was provided to permit
clear judgement of this aspect.
• Inadequate: if not all relevant outcomes and prespecified
outcomes were reported, or if they were incompletely reported.
Other sources of bias
• Adequate: if the study appeared to be free of other sources
of bias, with special attention to funding source and potential
conflicts of interest.
• Unclear: if a risk of potentially important bias exists, but
sufficient information to assess this bias was lacking.
• Inadequate: if one or more sources of potentially important
bias could be identified in the study (e.g. extreme baseline
imbalances, other imbalances in study design).
Cross-over trials
For cross-over trials, we have examined the following additional
sources of bias according to the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2008a).
• Suitability of the cross-over design.
• Whether a carry-over effect was present, and if first period
data were presented.
These aspects are discussed and are notedunder the heading ’Other
sources of bias’ when concerns are present in individual trials.
Measures of treatment effect
Statistical analyses of binary data were conducted using risk ratios
(RRs). Trials with zero events in both arms were excluded from
meta-analyses. As a robustness assessment,meta-analyses with zero
event trials were performed using risk differences in a sensitiv-
ity analysis. For continuous outcomes, weighted mean differences
(WMDs)were preferably used, but when different scales were used
for the same outcome, we used the standardised mean difference
(SMD) instead.When datawere presented asmedianswith ranges,
study authors were contacted and were asked to provide additional
data. If data could not be retrieved, a sensitivity analysis imputing
data for missing means and standard deviations (calculated from
available medians and ranges) was performed as well (Hozo 2005).
Assessment of heterogeneity
Heterogeneity was calculated using the Higgins Chi2 test, and
inconsistency in study effects was quantified by I2 (Higgins 2002).
A Chi2 test with a P value < 0.10 was considered to indicate the
presence of heterogeneity, and an I2 > 50% was considered to
suggest marked inconsistency in effect between studies.
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Assessment of reporting biases
Funnel plots were used to provide a visual assessment of whether
treatment estimates were associated with study size. These depic-
tions may reveal the presence of publication or other types of bias
(Begg 1994; Egger 1997; Macaskill 2001).
Data synthesis
Parallel trials
The inverse variance and Mantel-Haenzel methods were used for
continuous and dichotomous outcomes, respectively.
Cross-over trials
For continuous outcomes, the generic inverse variance method
using mean differences and standard errors from paired analysis
was used for meta-analysis. If no paired data were available, we re-
frained from pooling data from cross-over trials. In these cases, we
performed a sensitivity analysis by combining parallel and cross-
over trials using unpaired data, as outlined below.
For dichotomous outcomes, the literature suggests that paired and
unpaired analyses can be suitable for meta-analysis (Curtin 2002;
Elbourne 2002). Both types of analysis yield similar effect esti-
mates, but the unpaired analysis yields a wider confidence inter-
val (a more conservative estimate). If possible, we adjusted the
variance using the Becker and Balagtas method (Elbourne 2002;
Stedman 2011). Advantages of this approach are that values are
easily calculated and this method allows for combinations of cross-
over and parallel trials while harnessing the power of cross-over
studies. The disadvantage is that this approach requires reporting
of additional data, which might not be available. If such data were
not available, an unpaired analysis was performed.
Combining parallel and cross-over trials
When paired data from cross-over trials were available, we com-
bined these with data from parallel trials using the general inverse
variance method. Paired data from cross-over trials were entered
into this model directly. For parallel trials, mean difference and
standard error (calculated from the 95% confidence interval (CI))
were used for this purpose.
If no paired data were available, we performed a sensitivity anal-
ysis by combining unpaired data from cross-over trials with data
from parallel trials. For this approach, the usual methods of meta-
analysis were used.
For all meta-analyses, the fixed-effect model was used if no het-
erogeneity was present (Chi2 P value > 0.1 and I2 < 50%), or the
random-effects model was used. Statistical analysis was conducted
using the statistical package RevMan v.5.2.5, as provided by The
Cochrane Collaboration (RevMan 2014).
R E S U L T S
Description of studies
Results of the search
We performed the search on 16 October 2012 and obtained a
total of 489 citations. Upon selection, we found a total of 19 eli-
gible citations describing 11 distinct RCTs (Figure 1). All studies
excluded after the first selection are listed along with reasons for
exclusion in the Characteristics of excluded studies table. Cross-
reference searching of all included randomised trials revealed one
additional potentially eligible article (Nandi 2002). Cross-refer-
ence searching of two relevant reviews (Bjelakovic 2008;Monfared
2009) yielded no further eligible articles. Therefore, a total of 20
citations describing 12 distinct trials were included. By means of
personal communication, we identified one ongoing trial, EU-
ROPAC-2. Details of this trial are described in the Characteristics
of ongoing studies table.
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Figure 1. Study flow diagram.
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Included studies
Eight of the 12 included trials were double-blind, placebo-con-
trolled trials, and one trial was single-blinded (Durgaprasad 2005).
Six trials used a cross-over design, and six a parallel-group design.
Two trials were published only in abstract form (Deprez 2003;
Nandi 2002). Trial sizes varied from 14 to 147 participants. Three
trials (Bilton 1994a; Bilton 1994b; Uden 1990) included only
participants with recurrent pancreatitis of non-gallstone origin
(mostly alcohol). Durgaprasad 2005 excluded patients with alco-
holic CP, and Kirk 2006 excluded patients with CP who had gall-
stones. The other trials included participants with established CP
of all etiologies. Trials used a variety of antioxidants and reported
on various outcomes. Most trials assessed pain using a visual ana-
logue scale (VAS) (Hawker 2011); however different scales and
methods of reporting were used (Table 1).
Elevenof the 12 included trials described the effects of antioxidants
on chronic abdominal pain inCP.One trial (Salim 1991) evaluated
the effects of antioxidants on acute pain during exacerbations of
CP. As this is a different indication, results of this trial are described
separately.
Ten trials compared antioxidant treatment versus placebo. Deprez
2003 compared antioxidants with dietary counselling versus di-
etary counselling alone but published no data that were suitable
for meta-analysis. Jarosz 2010 compared antioxidants versus no
intervention (standard treatment). Given the availability of data,
we performed only one of the three comparisons we had set out
to perform (i.e. antioxidants vs placebo/no intervention).
Further characteristics of included trials are described in the
Characteristics of included studies table. Baseline characteristics
of included participants are described in Table 2.
Excluded studies
Reports excluded after initial screening of titles and abstracts are
listed along with reasons for exclusion in the Characteristics of
excluded studies table.
Risk of bias in included studies
A risk of bias summary table of included trials is presented inFigure
2.Themost commonweakness of included trialswas that outcome
data were incomplete (high dropout rates, see below). Regarding
other items, a division can be made between well-conducted trials
with relatively low risk of bias (Banks 1997; Bhardwaj 2009; Bilton
1994a; Bilton 1994b; Siriwardena 2012; Uden 1990) and poorly
conducted trials with higher risk of bias.
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Figure 2. Summary of risk of bias: review authors’ judgements about each risk of bias domain for included
trials.
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Dropout rates
The dropout rates of individual trials, the distribution of drop-
outs among trials arms and the reasons for dropout are stated in
the ’Risk of bias table’ sections of the Characteristics of included
studies. In the studies Bilton 1994a and Bilton 1994b, most drop-
outs were in the antioxidant arms and most cases of dropout were
due to adverse events. In all other trials, dropouts were similarly
divided between trial arms.
Cross-over trials
Appropriateness of the cross-over design
CP is a chronic condition, making it a good candidate for cross-
over trials. The major outcomes of these studies (i.e. pain, quality
of life, antioxidant levels, number of pancreatitis attacks) are re-
versible outcomes, which are suitable for this design. Antioxidant
supplementation is a reversible treatment, and its effects are gener-
ally short-lasting. However, two facts need to be noted: (1) Some
antioxidants (e.g. vitamin E) are fat soluble, allowing for long-
term storage (in contrast to water-soluble antioxidants, which are
excreted immediately). This might result in some carry-over effect
if levels remain high in the second period; and (2) themechanisms
by which antioxidants might work in CP are not entirely eluci-
dated. Although the major hypothessed action is reversible (i.e.
countering the high free radical state in CP), it cannot be ruled out
that some mechanisms might have longer-lasting effects. There-
fore, empirical data from these trials must be evaluated to rule out
any carry-over effect.
Carry-over effect
Published reports of all cross-over trials, exceptDeprez 2003 (pub-
lished as abstract only), discussed the risk of carry-over effect. Both
Uden 1990 and Banks 1997 statistically investigated the presence
of carry-over effect and stated that they did not identify a signif-
icant carry-over effect in clinical or biochemical outcomes. Uden
1990 used the fat-soluble vitamin E, and its levels showed no signs
of a carry-over effect at the end of the second study period. Bilton
1994a and Bilton 1994b describe the analysis performed by Uden
1990 because these trials were performed by the same group. Kirk
2006 showed that biochemically the levels of fat-soluble vitamin E
tended to remain slightly elevated until the end of the study. These
study authors identify this as a potential limitation of the study
but conclude that it would have resulted in a bias towards the zero
(no) effect, although this study showed a significant difference in
clinical outcome. Based on these results, we can conclude that em-
pirical evidence shows that the carry-over effect does not play an
important role in this comparison.
Publication bias
Publication bias was evaluated by means of funnels plots, but no
clear evidence of such bias was observed (Figure 3).
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Figure 3. Evaluation of publication bias by funnel plot (based on the outcome ’adverse effects’).
Effects of interventions
See: Summary of findings for themain comparisonAntioxidant
versus control intervention for pain in chronic pancreatitis
Effects of antioxidants on chronic pain in chronic pancreatitis
Primary outcome-pain
An overview of the results of different pain outcome measures
reported by the included trials is presented in Table 3.
Eight trials assessed pain using a VAS score (Table 1). Not all
data were suitable for meta-analysis. Bilton 1994a and Bilton
1994b reported that no significant difference was noted but did
not provide any data. Kirk 2006 excluded the VAS score from
analysis because of poor reporting by participants. Deprez 2003
reported only baseline VAS scores.
Pain VAS scores from two cross-over trials were pooled (Analysis
1.1), showing a significant reduction in pain VAS scores in favour
of the antioxidant group (MD -0.34 VAS points, 95% CI -0.67 to
-0.01, P value 0.04) (Analysis 1.1). Two trials with a parallel-group
design were pooled, showing no difference in pain levels (MD -
0.26, 95% CI -1.07 to 0.56, P value 0.5) (Analysis 1.2). When
results of all trials were combined (118 participants), a significant
reduction in VAS score was observed in the antioxidant groups
(MD -0.33, 95% CI -0.64 to -0.02, P value 0.04) (Analysis 1.3).
Three parallel trials reported the proportion of pain-free partic-
ipants as an outcome measure. Meta-analysis showed a non-sta-
tistically significant difference between groups (RR 1.73, 95% CI
0.95 to 3.15, P value 0.07) (Analysis 1.4).
Secondary outcomes
Adverse effects and mortality
Eight trials reported adverse effects. In total, 33 of 208 (16%)
adverse events were reported in the antioxidant group compared
with five of 196 (3%) in the placebo group. Separate analysis of
cross-over trials (RR 5.80, 95% CI 1.56 to 21.53, P value 0.009)
and parallel trials (RR 4.43, 95%CI 1.60 to 12.29, P value 0.004)
showed significantly higher adverse events in the antioxidant group
(Analysis 1.5). Analysis of cross-over trials was based on unpaired
data because reported data did not allow for correction of vari-
ance. Sensitivity analyses combining cross-over and parallel trials
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(Analysis 1.6) and data for zero event trials using risk differences
produced similar results (Analysis 1.7). Most reported adverse
events wereminor complications and included headache, gastroin-
testinal intolerance, obstipation and nausea. Only two moderate
to severe adverse effects were described. Banks 1997 reported that
one participant developed swelling of joints, a rash and a puffy
face. Siriwardena 2012 described one participant in the antiox-
idant group who developed convulsions as the result of hepatic
encephalopathy, although the relation of this to antioxidant treat-
ment was uncertain. No trials reported any mortality.
Pain medication
Three trials including 210 participants reported on the need for
pain medication during the study period. Data appeared unsuit-
able for meta-analysis. Banks 1997 showed no difference in the
need for morphine use between participants given antioxidants
and those given placebo (increase of 5.5%, range -49% to +129%).
Bhardwaj 2009 reported a positive effect of antioxidants compared
with placebowhen evaluating the numbers of oral analgesic tablets
required per month (MD -6.15, 95% CI -2.65 to -9.65). Similar
results were found for the numbers of analgesic injections required
per month after adjustment for baseline differences (MD -0.44,
95%CI -0.07 to -0.81). Siriwardena 2012 described no difference
in the need for opioid analgesic when antioxidants were used (MD
-13.7 mg/d, 95% CI -38.0 to 10.6).
Quality of life
Three trials including 102 participants reported on quality of life.
Data were unsuitable for meta-analysis. Banks 1997 reported on
activities of daily living and described no differences between an-
tioxidants and placebo (MD -3.3, 95% CI -10.3 to 3.7, P value
0.32). Kirk 2006 assessed quality of life using the 36-Item Short
FormHealth Survey (SF-36) questionnaire. Resultswere presented
for nine components separately. Six of the quality of life com-
ponents (physical function, physical role, social function, pain,
health perception and change in health) showed significant im-
provement in the antioxidant group compared with the placebo
group. Siriwardena 2012 examined quality of life using four dif-
ferent quality of life questionnaires. None revealed a significant
difference.
Admissions and duration of hospital stay
Two trials including 197 participants reported on this outcome.
Bhardwaj 2009 reported on the need for hospitalisation. A small
difference was observed in favour of antioxidant use after adjust-
ment for baseline values (MD -0.034, 95% CI -0.069 to -0.002).
Siriwardena 2012 showed no differences between study groups
(MD -0.06, 95% CI -3.80 to 3.53).
Number of attacks of pancreatitis
Three cross-over trials including 54 participants reported the fre-
quency of severe attacks of pancreatic pain. Fifteen attacks oc-
curred: five in the antioxidant period and 10 in the placebo period.
This difference was not statistically significant (Analysis 1.8). This
analysis was based on unpaired data, as reported data did not allow
for correction of variance.
Loss of workdays
Only Bhardwaj 2009 (127 participants) reported on the number
of workdays lost. This trial reported a favourable larger decrease in
workdays lost in the antioxidant group compared with the placebo
group (11.4 ( SD 9.1) vs 7.6 ( SD 7.2), P value 0.014).
Antioxidant level measures
Most studies reported several measures of antioxidant status. Four
of these measures were reported by three or more trials and were
chosen for meta-analysis (i.e. vitamin C and A, selenium and beta-
carotene). All cross-trials reported unpaired data for this outcome
and could be included only in sensitivity analyses. Main meta-
analyses based on parallel trials showed significantly higher levels
of vitamins C and E in the antioxidant groups (Analysis 1.9;
Analysis 1.11). Sensitivity analysis of these outcomes confirmed
these findings (Analysis 1.10; Analysis 1.12). Finallly, sensitivity
analysis of selenium and beta-carotene suggested higher levels in
the antioxidant groups (Analysis 1.13; Analysis 1.14).
Effects of antioxidants on acute pain in chronic pancreatitis
Primary outcome-pain
Salim 1991 included patients with CP within two hours of onset
of an acute pain episode. Participants were randomly assigned to
three groups: two antioxidant groups (allopurinol and dimethyl-
sulfoxide) and a placebo group. This trial assessed the proportions
of pain-free participants in the three study groups at different mo-
ments during admission. After 12 hours of admission, the propor-
tions of pain-free participants were significantly higher in the two
antioxidant groups than in the placebo group (respectively, 13/22
(59%) and 12/21 (57%) vs 4/23 (17%); P value < 0.01). After 24
hours, all participants in the two antioxidant groups achieved pain
relief versus 12 of 23 (52%) in the placebo group (P value < 0.01).
Additionally, after two days, all participants in the placebo group
experienced epigastric tenderness versus 12 of 22 (54%) in the
allopurinol group and 11 of 21 (52%) in the dimethylsulfoxide
group (P value < 0.01). After three days, only four of 22 (18%)
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and three of 21 (14%) participants, respectively, in the allopurinol
and dimethylsulfoxide groups, experienced epigastric tenderness,
and 17 of 23 (74%) in the placebo group had epigastric tenderness
(P value < 0.01).
Secondary outcomes
This trial reported on only two of the secondary outcomemeasures
(i.e. adverse effects and hospital stay) (Salim 1991). Five (23%)
participants in the allopurinol group experienced adverse effects,
including allergic reactions (rash) and headaches. A total of four
(19%) participants in the dimethylsulfoxide group experienced
adverse effects (intolerance tomedication (1×) and headache (3×)).
None of the participants in the placebo group reported any adverse
effects.
This trial also reported the proportions of participants discharged
from hospital after three days. All participants in the allopurinol
(n = 22) and dimethylsulfoxide (n = 21) groups were discharged
home after three days compared with five of 23 (22%) in the
placebo group (P value < 0.01).
D I S C U S S I O N
Summary of main results
This systematic review shows several important findings regarding
antioxidant treatment in chronic pancreatitis. First, it shows that
antioxidant use may reduce pain in chronic pancreatitis. Second, it
shows that antioxidant use is associatedwith adverse effects in 16%
of patients. Although mostly mild in nature, these adverse effects
sometimes result in discontinuation of antioxidant medication.
Third, 12 randomised trials have been conducted, but these trials
included small sample sizes, suffered high rates of dropout andwere
inadequate in reporting of outcomes critical for decision making.
Meta-analysis of pain VAS scores showed a significant reduction
favouring antioxidant treatment. This result was based on the find-
ings of four trials, three of which had adequate methodology for
most items included in the risk of bias tool (Figure 2). The con-
tribution of the fourth trial was limited (weight in the analysis
was 3%). No heterogeneity was observed between studies (I2 =
0%). All of these aspects increase the reliability of the findings.
The marginal statistical significance (P value 0.04) on the other
hand is probably an indication of the small numbers of included
participants. The overall VAS score was only slightly reduced by
antioxidants (0.33 of 10 points) (Analysis 1.3). Such a small dif-
ference is of unclear clinical relevance, and its clinical impact is
uncertain.
A factor contributing to reported outcomes could be that most
participants in the trials had only mild pain. (The pain VAS score
under placebo treatment was around three points in most trials.)
When the VAS pain score was higher, as in Durgaprasad 2005,
the absolute reduction tended to be greater (e.g. a reduction of -
0.76 from a placebo VAS of 6.57) (Analysis 1.2). The proportion
of pain-free participants offers a more clinically relevant outcome.
Our meta-analysis shows that the difference in this outcome was
not statistically significant, although a trend favouring antioxidant
treatment was observed (Analysis 1.4). It is clear that more evi-
dence is needed to establish or reject potential differences.
Another important outcome for clinical practice is the adverse
events observed in 16% of participants treated with antioxidants
(Analysis 1.6). Although most adverse events were mild, trial au-
thors reported that participants often decided to discontinue an-
tioxidant treatment because of these events.
Other important secondary outcomes, such as use of pain medi-
cation, rate of exacerbation of pancreatitis and quality of life, were
not well evaluated in the included trials, and data were insufficient
to permit reliable conclusions. Future trials need to consider these
outcomes and preferably present data in ways that facilitate meta-
analysis, by reporting complete outcome data and choosing out-
come measures comparable with those of previous studies.
Overall completeness and applicability of
evidence
Inclusion criteria varied between trials. Some trials included only
non-alcoholic participants with CP, and others recruited all pa-
tients with CP, including those with recurrent attacks of pancre-
atitis. This is representative of the heterogeneity of patients with
CP and may justify an argument regarding the generalisability of
the results of this review. A noteworthy aspect based on the hy-
pothesised mechanism of antioxidant treatment is the duration
of disease at the time of antioxidant therapy. Antioxidant therapy
is hypothesised to reduce damage to the pancreas caused by ox-
idative stress. Maximal benefit is likely to be achieved when an-
tioxidants are administered early in the disease process (before the
damage has been done) and are continued for a substantial time.
This aspect did not receive attention in the included trials. Only
a few reported the duration of disease of included participants
(Table 2), and none performed subgroup analysis based on this
characteristic. The limited number of participants may have been
a contributing factor in this regard.
Variation in reporting of outcome measures posed an important
challenge for a summary of results (e.g. nearly all trials measured
pain using a VAS score, but only four trials reported data that
were suitable for meta-analysis). Contacting study authors was not
helpful, as most trials were conducted more than 15 years ago
and original data were no longer available. In two studies, trial
authors stated only the absence of a significant difference without
presenting data (Bilton 1994a; Bilton 1994b). This way of report-
ing should be avoided because pooling of trial data could expose
differences in treatments not observed in single trials. These trials
also used different types of antioxidant regimens, with variations
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evident in types, numbers of preparations and doses of antioxi-
dants used. Because of the small number of available trials, the in-
fluence of different regimens could not be evaluated in subgroups.
Moreover, the lack of trials comparing different types of antioxi-
dants makes direct comparison not feasible. Finally, only one trial
studied the effects of antioxidants on acute pain in chronic pancre-
atitis. More evidence is needed before conclusions can be drawn.
Quality of the evidence
The 12 RCTs included a total of 585 participants. The most im-
portant limitation was the high rate of dropout due to adverse
events or non-compliance. Six trials were relatively well conducted
in terms of adequate randomisation, concealment of allocation,
blinding and placebo control (Banks 1997; Bhardwaj 2009; Bilton
1994a; Bilton 1994b; Siriwardena 2012; Uden 1990), but the re-
maining trials had serious methodological flaws (Figure 2). An-
other important limitation was the small sample size of most trials.
Eight of the included trials recruited fewer than 40 participants.
This is to some extent attenuated by a cross-over design in some
trials, in that this design allows more power than is attained by
a parallel-group design. Still, most trials were underpowered to
detect any differences in clinically important outcomes.
Potential biases in the review process
Inconsistent reporting posed the most important challenge to this
systematic review. Two randomised trials (Deprez 2003; Nandi
2002) were published only as abstracts and did not contribute
data on any of the comparisons. This kind of publication bias has
been widely acknowledged to be problematic, but solutions such
as trial registration have already led to progress in resolution of
this problem (McGee 2011). Second, we were unable to obtain
suitable data for several outcomes. This was due mainly to incom-
plete reporting of trial data and to the fact that most trials were
conducted some time ago. Third, the cross-reference search iden-
tified one additional eligible report not identified by our electronic
search. This report was published as an abstract in a supplement
that was not indexed in any electronic database (Nandi 2002).
This again shows that cross-reference searching of included trials
is an important step in the search process. Fourth, the use of un-
paired data might lead to underestimation of the true level of sta-
tistical heterogeneity owing to the inflation of confidence intervals
(as a result of the more conservative estimation). Although this
can affect results in general, for our review the impact is probably
limited. Heterogeneity estimates were consistent for all outcomes
between estimates from parallel trial analysis and those from sensi-
tivity analysis, including unpaired data. For the only outcome with
exclusively unpaired data from cross-over trials, heterogeneity was
found to be significant, thus negating this potential bias. Finally,
our search was conducted more than one year ago, meaning that
some recent publications might have been missed. This lag is due
to the fact that several steps in the process took more time than
was anticipated. For practical reasons, we have planned an update
of the review early next year, to keep results of this review recent
and relevant.
Agreements and disagreements with other
studies or reviews
A recent systematic review of antioxidant therapy in pancreatitis
(Monfared 2009) was unable to provide clear conclusions about
the benefit of antioxidant therapy and underlined the need for
additional research. This review, however, included trials on both
acute and chronic pancreatitis. These diseases were discussed si-
multaneously, and conclusions were not always clearly separated.
Because of the distinct pathophysiological and clinical presenta-
tion of acute and chronic pancreatitis, combining trials on both
diseases into a single analysis may be inappropriate. This review
stratified the analysis per types of antioxidants used. Although this
is a more precise approach, the lack of data for each type of an-
tioxidant limits the possibility of useful conclusions. The fact that
trials use various types of antioxidants indicates that clinicians are
more interested in studying the hypothesis that reducing oxida-
tive stress may improve health outcome than in evaluating which
substance is more efficient. The review concluded that trials were
heterogeneous and that drawing conclusions was impossible. The
review authors stated that based on the results of the largest trial by
Bhardwaj 2009, treatment with cocktails of oxidants could have a
positive effect on pain reduction.
Another review (Braganza 2010) discussed the role of micronutri-
ent therapy in CP and described the role of antioxidants as part
of the review. This review concluded that antioxidants can con-
trol background pain and can curb acute attacks in chronic pan-
creatitis. A drawback of the Braganza 2010 review is the lack of
assessment of risk of bias of the included trials. Moreover, since
time of the Braganza review, two new trials have been published,
which were not included in that review. Finally, both of the reviews
discussed here (Braganza 2010; Monfared 2009) lacked quantita-
tive assessment of various important outcomes, especially adverse
events, although these data were available.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current evidence shows that antioxidants can reduce pain slightly
in patients with CP, but the clinical relevance of the small observed
difference is uncertain. With such small effects, routine use of an-
tioxidants is questionable. In a minority of patients, the use of an-
tioxidants can lead to mild adverse effects (headache and gastroin-
testinal intolerance), which can mandate cessation of treatment.
16Antioxidants for pain in chronic pancreatitis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Effects of antioxidants on other outcomes are still largely uncertain
because of lack of data. Antioxidants also seem to benefit patients
with CP during acute abdominal pain episodes (exacerbations),
although evidence is insufficient for reliable conclusions.
Implications for research
Topics that have not been sufficiently evaluated include:
• providing additional data on the effects of antioxidants on
pain, especially in terms of outcomes with clear clinical
relevance, such as becoming pain free;
• clarifying the effects of antioxidants on secondary outcomes
such as quality of life and rate of pancreatitis flare-ups; and
• studying whether the timing of intervention (early
intervention) can affect the outcome of antioxidant treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Banks 1997
Methods • Type of trial: double-blind, randomised, placebo-controlled, cross-over trial
• Duration of intervention: antioxidant or placebo (4 weeks), washout period (2
weeks), cross-over to placebo or antioxidant (4 weeks)
Participants • 16 participants (aged > 18 years) with CP who experienced continuous or
intermittent episodes of pain (> 2 episodes/wk)
Interventions • Intervention: allopurinol 300 mg/d
• Control: identical placebo
Outcomes • Pain:
◦ Pain scores (descriptive pain intensity scale, numerical pain intensity scale
and visual analogue scale)
◦ McGill Pain Questionnaire
• Use of pain medications: recorded by participants on a daily basis
• Activities of daily living: weekly activities of daily living questionnaire
• Mean uric acid levels: measured at beginning of treatment, at week 2 and at the
end of each treatment period
• Adverse effects
Notes Study performed in Boston, United States of America
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generated by hospital
pharmacy
Allocation concealment (selection bias) Low risk Randomisation concealed by hospital phar-
macy
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded. Placebo was identical to
intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 of 16 (38%) participants withdrew
3 did not come to the clinic before the
start of study medication (all in allopurinol
group). 2 participants (1 in each group) dis-
continued because of adverse experiences.
1 participant in the placebo first group
withdrew from the study at the end of the
washout period
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Banks 1997 (Continued)
Selective reporting (reporting bias) Low risk No protocol available. All outcomes men-
tioned in methods are shown in the results
Other bias Low risk No other biases identified
Bhardwaj 2009
Methods • Type of trial: parallel, double-blind, randomised, placebo-controlled trial
• Duration of intervention: 6 months
Participants • 147 patients with CP (aged > 12 years) presenting with significant pancreatic
pain. Pain was considered significant if at least 1 episode of pain every month required
analgesics during the preceding 3 months, or at least 1 episode of severe pain required
hospitalisation during the preceding 3 months
Interventions • Intervention: combination antioxidants (daily 600 µg selenium, 0.54 g ascorbic
acid, 9000 IU β-carotene, 270 IU α-tocopherol and 2 g methionine)
• Control: identical placebo
Outcomes • Pain: reduction in number of painful days per month
• Use of pain medication: numbers of oral analgesic tablets and parenteral
injections per month
• Number of attacks of pancreatitis: number of attacks of severe pancreatitis
requiring hospitalisation
• Man-days lost: number of man-days lost per month
• Oxidative stress markers and antioxidant status
• Adverse effects
Notes Study performed in New Delhi, India
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence was computer-gener-
ated by independent statistician
Allocation concealment (selection bias) Low risk Concealed allocation. Separate individuals
generated the allocation sequence, enrolled
participants and assigned participants to
groups
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded. Placebo was identical to
intervention
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Bhardwaj 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk In total, 40 (27%) participants (27 in the
placebo group and 13 in the intervention
group) were lost at some time during the
study. Not all reasons for these losses are
specified
Selective reporting (reporting bias) Low risk The study protocol is available. All out-
comes in the protocol were reported. Addi-
tionally, the number of man-days lost per
month as the result of pain was reported
in the article but was not specified in the
protocol
Other bias Low risk No other biases identified
Bilton 1994a
Methods • Type of trial: double-blind, randomised, placebo-controlled, cross-over trial
(Braganza 2010)
• Duration of intervention: antioxidants or placebo (10 weeks), cross-over (no
washout period) to placebo or antioxidants (10 weeks)
Participants • 30 participants with:
◦ recurrent acute pancreatitis, at least 2 documented attacks of pancreatitis in
the previous year
◦ CP, constant pain suggestive of a pancreatic origin, including ’alcoholic’
(weekly equivalent of > 60 g per day in women or > 80 g per day in men for at least 1
year before the first attack) and idiopathic cases
• Participants with acute pancreatitis and CP were randomly assigned separately




◦ Daily pain diary: visual analogue scale
◦ Descriptive pain score sheet: incorporating 11 descriptors of pancreatic pain
• Attacks of pancreatitis: verified by general practitioners at 10 weeks and at the end
of the study
• Oxidative stress markers and antioxidant status
Notes Study performed in Manchester, England
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Bilton 1994a (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Randomisationwas concealed by envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded study, using placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk 10 of 30 (33%) participants withdrew (6
for gastrointestinal intolerance, 3 requiring
urgentmedical treatment, 1whodefaulted)
Selective reporting (reporting bias) Low risk No discrepancies between methods and re-
sults
Other bias Low risk No other biases identified
Bilton 1994b
Methods • Type of trial: double-blind, randomised, placebo-controlled, cross-over trial
(Braganza 2010)
• Duration of intervention: antioxidants or placebo (10 weeks), cross-over (no
washout period) to placebo or antioxidants (10 weeks)
Participants • 14 participants with:
◦ recurrent acute pancreatitis, at least 2 documented attacks of pancreatitis in
the previous year
◦ CP, constant pain suggestive of a pancreatic origin, including ’alcoholic’
(weekly equivalent of > 60 g per day in women or > 80 g per day in men for at least 1
year before the first attack) and idiopathic cases
• Participants with acute pancreatitis and CP were randomly assigned separately
Interventions Intervention: combination antioxidants (daily 800 mg S-adenosylmethionine (SAMe)
sulfate-p-toluenesulfonate and 600 µg selenium and 9000 IU β-carotene)
Control: placebo
Outcomes • Pain:
◦ Daily pain diary: visual analogue scale
◦ Descriptive pain score sheet: incorporating 11 descriptors of pancreatic pain
• Attacks of pancreatitis: verified by general practitioners at 10 weeks and at the end
of the study
• Oxidative stress markers and antioxidant status
Notes Original goal was to include 30 participants. Study was terminated early because of
adverse events
Study performed in Manchester, England
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Bilton 1994b (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Randomisationwas concealed by envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded study, using placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 (43%) of 14 patients withdrew (3 for gas-
trointestinal adverse effects, 2 with unre-
lated medical problems, 1 who defaulted)
Selective reporting (reporting bias) Low risk No discrepancies between methods and re-
sults
Other bias High risk Study was terminated early as the result of
unexpected adverse events. No formal stop-
ping rule was applied, and study authors
did not state that analysis was corrected for
early termination
Deprez 2003
Methods • Type of trial: open, randomised, controlled, cross-over trial
• Duration of intervention: dietary counselling with antioxidants vs dietary
counselling alone (3 months), cross-over (no washout period) to dietary counselling
alone or antioxidants with dietary counselling (3 months)
Participants • 30 participants (aged 18 to 60 years) with CP (not further specified). Average pain
VAS was 31.7%
Interventions • Intervention: dietary counselling plus antioxidant supplementation (3 times daily
Quatral, containing 25 mg vitamin E, 120 mg vitamin C, 6 mg β-carotene (1 mg
vitamin A), 100 µg selenium, 15 mg zinc)
• Control: dietary counselling aiming to correct all errors detected during a
preliminary dietary evaluation
Outcomes • Diatary assessment
• Pain: pain visual analogue scale (VAS) and number of participants with pain
• Oxidative stress markers and antioxidant levels
• Nutritional and metabolic assessment (BMI, fat mass, basal metabolism)
• Exocrine and endocrine pancreatic function.
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Deprez 2003 (Continued)
Notes • Published only in abstract form
• Study performed in Brussels, Belgium
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
High risk Not performed (open trial)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk Published only in abstract form. Pain data
not well reported
Other bias Unclear risk Published only in abstract form
Durgaprasad 2005
Methods • Type of trial: parallel, single-blind, randomised, placebo-controlled trial
• Duration of intervention: 6 weeks
Participants • 20 participants (aged 18 to 65 years) with non-alcoholic CP, with abdominal pain
not related to other gastrointestinal or systemic disease
Interventions • Intervention: combination antioxidants (3 times daily 500 mg curcumin and 5
mg piperine)
• Control: identical placebo
Outcomes • Pain: visual analogue scale assessed before and after treatment
• Use of pain medication
• Oxidative stress markers and antioxidant status
• Adverse effects
Notes Study performed in Manipal, India
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Durgaprasad 2005 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method of randomisation is not described
Allocation concealment (selection bias) Unclear risk Not described




Incomplete outcome data (attrition bias)
All outcomes
High risk 5 (25%) participants did not return for
evaluation and were not assessed
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods are
shown in results. Data on use of analgesics
not shown but use of analgesics is shortly
described. No protocol available
Other bias Unclear risk Study authors say diabetic patients will be
excluded, but in the characteristics of par-
ticipants section, 6 are described as having
diabetes mellitus
Jarosz 2010
Methods • Type of trial: parallel, open, randomised, controlled trial
• Duration of intervention: 6 months
Participants 91 participants (aged 18 to 60 years) with proven (by imaging) alcoholic CP (daily 20
mL for 7 years), with abdominal pain
Interventions • Intervention: combination antioxidants (vitamin C and vitamin E)
• Control: standard treatment (i.e. no alcohol consumption, high-energy frequent
diet and painkillers (buskopan, paracetamol) if needed)
Outcomes • Number of participants becoming pain free
• Number of participants with attack of pancreatitis
• Disease-related complications (weight loss, exocrine and endocrine pancreatic
function)
• Oxidative stress markers and antioxidant status
Notes Study performed in Warsaw, Poland
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated. Stated only that a random code
was used
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Jarosz 2010 (Continued)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 24 (26%) of 91 participants were excluded:
10 in the standard treatment group, and 14
in the antioxidant group.Reasons for exclu-
sion: continued alcohol consumption, loss
to follow-up and lack of compliance with
study medication
Selective reporting (reporting bias) Low risk All outcomes in the methods section are
reported
Other bias Low risk No other biases identified
Kirk 2006
Methods • Type of trial: double-blind, randomised, placebo-controlled, cross-over trial
• Duration of intervention: antioxidants or placebo (10 weeks), cross-over (no
washout period) to placebo or antioxidants (10 weeks)
Participants • 36 participants (aged 16 to 75 years) with non-gallstone CP and chronic
abdominal pain. Participants had to meet 1 of the following criteria.
◦ Radiological abnormality of the pancreas consistent with CP (e.g.
calcification)
◦ Pancreatic duct abnormality at ERCP
◦ Evidence of exocrine pancreatic insufficiency on para-aminobenzoic acid
testing
Interventions • Intervention: combination antioxidants (4 times daily 75 µg selenium, 3 mg β-
carotene, 47 mg d-α-tocopherol acetate (vitamin E), 150 mg ascorbic acid (vitamin C)
and 400 mg methionine)
• Control: identical placebo
Outcomes • Pain: diaries incorporating visual analogue scales assessing pain intensity, pain
relief and mood on a daily basis
• Quality of life: Short Form-36 questionnaire
• Oxidative stress markers and antioxidant status
• Adverse effects
Notes Study performed in Belfast, Northern Ireland
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Kirk 2006 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation was not
specified
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind. Identical placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk 17 (47%) of 36 participants withdrew or
were lost to follow-up. 10 had first placebo
and 7 first antioxidants. This was attributed
to the length of the study period, poor par-
ticipant motivation and, in some cases, on-
going problems with alcohol dependence
Selective reporting (reporting bias) High risk No protocol available. Pain diaries were ex-
cluded from analyses because of inconsis-
tent completion
Other bias Low risk Fat-soluble vitamins such as vitamin E
tended to remain slightly elevated at the
end of the study, but results of this study
and of previous studies provide evidence
against a significant bias due to carry-over
effect
Nandi 2002
Methods • Type of trial: parallel, randomised, placebo-controlled trial
• Duration of intervention: 6 months
Participants • 25 patients with CP. No information regarding preintervention pain levels
Interventions • Intervention: combination antioxidants (daily 600 µg selenium, 0.54 g ascorbic
acid (vitamin C), 9000 IU β-carotene, 270 IU α-tocopherol (vitamin E) and 2 g
methionine)
• Control: placebo (unclear whether identical)
Outcomes • Pain: pain score (own scale, with maximal 12 points) and reduction in number of
painful days per month
• Oxidative stress markers and antioxidant status
Notes • Published only in abstract form
• Study performed in New Delhi, India
Risk of bias Risk of bias
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Nandi 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) High risk Published only as an abstract
Other bias Unclear risk Published only as an abstract
Salim 1991
Methods • Type of trial: parallel, 3-armed, double-blind, randomised, placebo-controlled trial
• Duration of intervention: until 24 hours pain free (mean = 45 hours)
Participants • 78 participants presenting at the hospital with a recurrent episode of abdominal
pain caused by alcohol-induced CP meeting the following criteria.
◦ Patient presented within 2 hours of onset of epigastric pain radiating to the
back
◦ No treatment had been given for the pain
◦ Patient had not abstained from alcohol
◦ No generalised peritonitis was clinically detectable
Interventions • Intervention arm 1: 4 times daily 50 mg allopurinol
• Intervention arm 2: 4 times daily 500 mg dimethylsulfoxide
• Control: 4 times daily placebo
Outcomes Participants were questioned 3 times each day and were physically examined twice daily
• Pain: percentage of participants becoming pain free 12, 24, 36 and 48 hours after
start of the intervention
• Percentage of participants with epigastric tenderness (daily)
• Percentage of participants tolerating free fluids for 12 hours (36, 48 and 72 hours
after start of treatment)
• Percentage of participants tolerating 3 solid meals (daily)
• Percentage of participants discharged home (daily)
• Serum: white blood cell count, amylase and lactate dehydrogenase
• Adverse effects
Notes Study performed in Baghdad, Iraq
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Salim 1991 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not stated
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded. Placebowas given in same
amount (iv) and on same schedule
Incomplete outcome data (attrition bias)
All outcomes
Low risk Four of 27 participants in the placebo
group, three of 25 in the allopurinol group
and five of 26 in the dimethylsulfoxide
group were not assessed. Reasons were
given. Both per-protocol and intention-to-
treat analyses were performed
Selective reporting (reporting bias) Unclear risk No protocol available. No clear specifica-
tion of outcomes in the methods section
Other bias Low risk No other biases
Siriwardena 2012
Methods • Type of trial: parallel, double-blind, randomised, placebo-controlled trial
• Duration of intervention: 6 months
Participants 70 patients with painful chronic pancreatitis (proven by imaging) with a baseline daily
pain score of 5 or greater for at least 7 days during a prerandomisation run-in period of
1 month
Interventions • Intervention: combination antioxidants (38.5 mg selenium yeast, of which 50 g l-
selenomethionine, 113.4 mg d-tocopherol acetate, 126.3 mg ascorbic acid and 480 mg
l-methionine)
• Control: identical placebo
Outcomes • Pain score: visual analogue score, change in pain score from baseline
• Pain diaries: daily pain scores (analysed as average of daily scores over study period)
• Brief Pain Inventory scores
• Quality of life questionnaires: EORTC-QLQC, QLQ-PAN28, EuroQOL, EQ-
5D and EQ visual analogue scale
• Oxidative stress markers and antioxidant status
• Use of opioid analgesics
• Hospital admissions for attacks of pancreatitis or complications
• Adverse effects
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Siriwardena 2012 (Continued)
Notes Study performed in Manchester, United Kingdom
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Concealed by central allocation (by phar-
macy)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, identical placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk 22 (23%) of 92 participants withdrew or
were lost to follow-up. Withdrawals were
similar, by treatment allocation and in age,
sex and baseline pain scores
Selective reporting (reporting bias) Low risk According to the registration form, the
study authors intended to also present
’Time in pain’ and ’Economic evaluation’
as part of their secondary outcomes. These
outcomes are not reported in the published
paper. However, these are secondary out-
comes that are not likely to significantly af-
fect the results of the trial
Other bias Low risk No other biases identified
Uden 1990
Methods • Type of trial: double-blind, randomised, placebo-controlled, cross-over trial
• Duration of intervention: antioxidants or placebo (10 weeks), cross-over (no
washout period) to placebo or antioxidants (10 weeks)
Participants • 23 patients with:
◦ recurrent acute pancreatitis, at least 2 documented attacks of pancreatitis in
the previous year, when ERCP and a test of exocrine pancreatic function were
unequivocally normal 6 to 8 weeks after recovery, or
◦ CP, constant pain suggestive of a pancreatic origin, including ’alcoholic’
(weekly equivalent of > 60 g per day in women or > 80 g per day in men for at least 1
year before the first attack) and idiopathic cases
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Uden 1990 (Continued)
Interventions • Intervention: combination antioxidants (daily 600 µg selenium, 9000 IU β-
carotene, 0.54 g vitamin C, 270 IU vitamin E, 2 g methionine)
• Control: identical placebo
Outcomes • Pain:
• ◦ Diaries incorporating a visual analogue scale completed on a daily basis
◦ Pain Vocabulary Scoresheet (at start, cross-over and end of study)
• Frequency of attacks of pancreatitis
• Psychological aspects: McGill Standard Pain Questionnaire, Zung Questionnaire,
pain experience questionnaire and pain locus of control
• Oxidative stress markers and antioxidant status
• Adverse effects
Notes Study performed in Manchester, England
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Double-blind, double-dummy, coordi-
nated by a senior pharmacist
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind. Identical placebos, except
for subtle differences (i.e. the selenium-
placebo had a distinctive sweet taste, and
the methionine-placebo lacked the garlic-
like odour of the true substance)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 (14%) participants lost to follow-up: 1 re-
quired surgery early in the trial, 1 got preg-
nant, 1 changed jobs and 1 was acciden-
tally changed from placebo to antioxidant
group
1 (4%) participant’s data were not analysed
because during the trial, after biochemical
analysis, it turned out that the participant
had high baseline levels of vitamin E (par-
ticipant was taking vitamin E-containing
supplement before the trial)
Selective reporting (reporting bias) Low risk All outcomes in the methods section are
reported
Other bias Low risk No other biases identified
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Abbreviations:
BMI: body mass index.
CP: chronic pancreatitis.
EORTC-QLQC: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
EQ-5D: EuroQOL 5-Dimension Questionnaire.
ERCP: endoscopic retrograde cholangiopancreatography.
EuroQOL: European Quality of Life Group.
QLQ-PAN28: Quality of Life Questionnaire-Pancreatic modification.
SAMe: S-adenosylmethionine.
VAS: visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bagul 2006 Not a randomised study
Bhardwaj 2004 Not a randomised study
Bhardwaj 2006 Not a randomised study
Braganza 1991 Book chapter. Review of topic
De las Heras 2000 Not a randomised study
Klapdor 2012 Not a randomised study. The intervention (vitamin D) is not a known antioxidant agent
Martinez-Torres 2009 Randomised controlled trial on acute pancreatitis
Matthew 1996 Not a randomised study (cross-sectional)
Milnerowicz 2005 Not a randomised study
Mosler 2005 Randomised controlled trial on acute pancreatitis
Nakamura 1996 Not a randomised study. Study focused on effect of pancreatic insufficiency
Romagnuolo 2008 Randomised controlled trial on acute pancreatitis
Shah 2010 Not a randomised study
Shalimar 2011 Not a randomised study
Sinwardena 2006 Randomised controlled trial on acute pancreatitis
Uden 1988 Not a randomised study (case-control study)
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Characteristics of ongoing studies [ordered by study ID]
EUROPAC-2
Trial name or title Pain Treatment of Hereditary and Idiopathic Pancreatitis
Methods 3-armed, double-blind, placebo-controlled, randomised, parallel-group study
Participants Patients with hereditary pancreatitis or idiopathic chronic pancreatitis
Interventions Group 1: daily doses of 300 µg organic selenium, 18 mg β-carotene, 750 mg vitamin C, 240 mg vitamin E,
2700 mg methionine
Group 2: magnesium-L-aspartate-hydrochloride 365 mg/d
Group 3: placebo
Outcomes Primary outcome measures:
• Reduction in number of days of pancreatic pain during 12 continuous months of treatment
Secondary outcome measures:
• Disruption of activities of normal living
• Analgesic use for pancreatic pain
• Number of days of hospitalisation for conditions related to pancreatitis
• Quality of life (QoL) measures
• Markers of inflammatory response and activity of the pancreas
• Changes in urinary levels of magnesium, selenium and vitamin C over the duration of the study
• Antioxidant response as measured by urinary thiobarbituric acid levels
• Response in participants with hereditary pancreatitis and idiopathic chronic pancreatitis
• Correlationg of response with gene mutations underlying hereditary pancreatitis (PRSS1, other) and
idiopathic chronic pancreatitis (SPINK1, CFTR, other)
• Data acquisition, including markers of inflammatory response during acute attack of chronic
pancreatitis
Starting date June 2004
Contact information Markus M Lerch, Professor of Medicine; 03834-86 ext 7230. lerch@uni-greifswald.de
Julia V Mayerle, MD; 03834-86 ext 7244. mayerle@uni-greifswald.de
Notes Contact: Julia V Mayerle, MD
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D A T A A N D A N A L Y S E S
Comparison 1. Antioxidant versus control intervention




participants Statistical method Effect size
1 Pain visual analogue scale
score-cross-over trials
2 44 Mean Difference (Fixed, 95% CI) -0.34 [-0.67, -0.01]
2 Pain visual analogue scale
score-parallel trials
2 85 Mean Difference (IV, Fixed, 95% CI) -0.26 [-1.07, 0.56]
3 Pain visual analogue scale
score-combined all trials
4 Mean Difference (Fixed, 95% CI) -0.33 [-0.64, -0.02]
4 Pain-free participants-parallel
trials
3 264 Risk Ratio (M-H, Random, 95% CI) 1.73 [0.95, 3.15]
5 Adverse effects 8 404 Risk Ratio (M-H, Fixed, 95% CI) 4.93 [2.21, 11.03]
5.1 Cross-over trials 5 192 Risk Ratio (M-H, Fixed, 95% CI) 5.8 [1.56, 21.53]
5.2 Parallel trials 3 212 Risk Ratio (M-H, Fixed, 95% CI) 4.43 [1.60, 12.29]
6 Adverse effects-sensitivity
analysis of parallel and
cross-over trials
8 404 Risk Ratio (M-H, Fixed, 95% CI) 4.93 [2.21, 11.03]
7 Adverse effects-sensitivity
analysis with risk difference
8 404 Risk Difference (M-H, Fixed, 95% CI) 0.13 [0.08, 0.19]
8 Number of pancreatitis
attacks-cross-over trials,
unpaired analysis
3 108 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.10, 4.10]
9VitaminC levels (mg/dL)-parallel
trials
3 237 Std. Mean Difference (IV, Random, 95% CI) 1.46 [1.00, 1.91]
10 Vitamin C levels
(mg/dL)-sensitivity analysis of
parallel and cross-over trials
6 343 Std. Mean Difference (IV, Random, 95% CI) 1.01 [0.48, 1.53]
11 Vitamin E levels
(mg/dL)-parallel trials
3 237 Std. Mean Difference (IV, Random, 95% CI) 1.32 [0.51, 2.13]
12 Vitamin E levels
(mg/dL)-sensitivity analysis of
parallel and cross-over trials
7 381 Std. Mean Difference (IV, Random, 95% CI) 1.12 [0.47, 1.78]
13 Selenium levels
(µg/dL)-sensitivity analysis of
parallel and cross-over trials
5 214 Mean Difference (IV, Random, 95% CI) 14.55 [4.38, 24.71]
14 β-Carotene levels
(µg/dL)-sensitivity analysis of
parallel and cross-over trials
5 214 Std. Mean Difference (IV, Random, 95% CI) 1.46 [0.44, 2.48]
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Analysis 1.1. Comparison 1 Antioxidant versus control intervention, Outcome 1 Pain visual analogue scale
score-cross-over trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 1 Pain visual analogue scale score cross-over trials





N N IV,Fixed,95% CI IV,Fixed,95% CI
Banks 1997 8 8 -0.28 (0.25) 45.8 % -0.28 [ -0.77, 0.21 ]
Uden 1990 14 14 -0.39 (0.23) 54.2 % -0.39 [ -0.84, 0.06 ]
Total (95% CI) 22 22 100.0 % -0.34 [ -0.67, -0.01 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Antioxidant versus control intervention, Outcome 2 Pain visual analogue scale
score-parallel trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 2 Pain visual analogue scale score parallel trials





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Durgaprasad 2005 8 5.81 (2.09) 7 6.57 (1.38) 21.2 % -0.76 [ -2.53, 1.01 ]
Siriwardena 2012 33 2.93 (1.96) 37 3.05 (1.96) 78.8 % -0.12 [ -1.04, 0.80 ]
Total (95% CI) 41 44 100.0 % -0.26 [ -1.07, 0.56 ]
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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37Antioxidants for pain in chronic pancreatitis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Antioxidant versus control intervention, Outcome 3 Pain visual analogue scale
score-combined all trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 3 Pain visual analogue scale score combined all trials





IV,Fixed,95% CI IV,Fixed,95% CI
Banks 1997 -0.28 (0.25) 39.3 % -0.28 [ -0.77, 0.21 ]
Durgaprasad 2005 -0.76 (0.9) 3.0 % -0.76 [ -2.52, 1.00 ]
Siriwardena 2012 -0.12 (0.469) 11.2 % -0.12 [ -1.04, 0.80 ]
Uden 1990 -0.39 (0.23) 46.5 % -0.39 [ -0.84, 0.06 ]
Total (95% CI) 100.0 % -0.33 [ -0.64, -0.02 ]
Heterogeneity: Chi2 = 0.54, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Antioxidant versus control intervention, Outcome 4 Pain-free participants-
parallel trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 4 Pain-free participants parallel trials








Bhardwaj 2009 23/71 7/56 26.7 % 2.59 [ 1.20, 5.60 ]
Jarosz 2010 22/32 11/35 34.4 % 2.19 [ 1.27, 3.76 ]
Siriwardena 2012 19/33 20/37 38.9 % 1.07 [ 0.70, 1.62 ]
Total (95% CI) 136 128 100.0 % 1.73 [ 0.95, 3.15 ]
Total events: 64 (Antioxidant), 38 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 6.82, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 1.80 (P = 0.073)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours control Favours antioxidants
39Antioxidants for pain in chronic pancreatitis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Antioxidant versus control intervention, Outcome 5 Adverse effects.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 5 Adverse effects
Study or subgroup Antioxidants Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cross-over trials
Banks 1997 1/13 1/13 14.7 % 1.00 [ 0.07, 14.34 ]
Bilton 1994a 6/30 0/30 7.4 % 13.00 [ 0.76, 220.96 ]
Bilton 1994b 3/14 0/14 7.4 % 7.00 [ 0.39, 124.14 ]
Kirk 2006 3/19 0/19 7.4 % 7.00 [ 0.39, 126.92 ]
Uden 1990 0/20 0/20 Not estimable
Subtotal (95% CI) 96 96 36.8 % 5.80 [ 1.56, 21.53 ]
Total events: 13 (Antioxidants), 1 (Control)
Heterogeneity: Chi2 = 2.02, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
2 Parallel trials
Bhardwaj 2009 12/71 3/56 49.3 % 3.15 [ 0.94, 10.64 ]
Durgaprasad 2005 0/8 0/7 Not estimable
Siriwardena 2012 8/33 1/37 13.9 % 8.97 [ 1.18, 67.97 ]
Subtotal (95% CI) 112 100 63.2 % 4.43 [ 1.60, 12.29 ]
Total events: 20 (Antioxidants), 4 (Control)
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.86 (P = 0.0042)
Total (95% CI) 208 196 100.0 % 4.93 [ 2.21, 11.03 ]
Total events: 33 (Antioxidants), 5 (Control)
Heterogeneity: Chi2 = 2.80, df = 5 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.00010)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 1.6. Comparison 1 Antioxidant versus control intervention, Outcome 6 Adverse effects-sensitivity
analysis of parallel and cross-over trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 6 Adverse effects sensitivity analysis of parallel and cross-over trials
Study or subgroup Antioxidants Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Banks 1997 1/13 1/13 14.7 % 1.00 [ 0.07, 14.34 ]
Bhardwaj 2009 12/71 3/56 49.3 % 3.15 [ 0.94, 10.64 ]
Bilton 1994a 6/30 0/30 7.4 % 13.00 [ 0.76, 220.96 ]
Bilton 1994b 3/14 0/14 7.4 % 7.00 [ 0.39, 124.14 ]
Durgaprasad 2005 0/8 0/7 Not estimable
Kirk 2006 3/19 0/19 7.4 % 7.00 [ 0.39, 126.92 ]
Siriwardena 2012 8/33 1/37 13.9 % 8.97 [ 1.18, 67.97 ]
Uden 1990 0/20 0/20 Not estimable
Total (95% CI) 208 196 100.0 % 4.93 [ 2.21, 11.03 ]
Total events: 33 (Antioxidants), 5 (Control)
Heterogeneity: Chi2 = 2.80, df = 5 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.00010)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Antioxidant versus control intervention, Outcome 7 Adverse effects-sensitivity
analysis with risk difference.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 7 Adverse effects sensitivity analysis with risk difference





n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Banks 1997 1/13 1/13 6.5 % 0.0 [ -0.20, 0.20 ]
Bhardwaj 2009 12/71 3/56 31.2 % 0.12 [ 0.01, 0.22 ]
Bilton 1994a 6/30 0/30 14.9 % 0.20 [ 0.05, 0.35 ]
Bilton 1994b 3/14 0/14 7.0 % 0.21 [ -0.02, 0.45 ]
Durgaprasad 2005 0/8 0/7 3.7 % 0.0 [ -0.22, 0.22 ]
Kirk 2006 3/19 0/19 9.5 % 0.16 [ -0.02, 0.34 ]
Siriwardena 2012 8/33 1/37 17.4 % 0.22 [ 0.06, 0.37 ]
Uden 1990 0/20 0/20 10.0 % 0.0 [ -0.09, 0.09 ]
Total (95% CI) 208 196 100.0 % 0.13 [ 0.08, 0.19 ]
Total events: 33 (Antioxidants), 5 (Control)
Heterogeneity: Chi2 = 13.46, df = 7 (P = 0.06); I2 =48%
Test for overall effect: Z = 4.53 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Antioxidant versus control intervention, Outcome 8 Number of pancreatitis
attacks-cross-over trials, unpaired analysis.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 8 Number of pancreatitis attacks cross-over trials, unpaired analysis








Bilton 1994a 2/20 3/20 40.8 % 0.67 [ 0.12, 3.57 ]
Bilton 1994b 3/14 1/14 33.8 % 3.00 [ 0.35, 25.46 ]
Uden 1990 0/20 6/20 25.5 % 0.08 [ 0.00, 1.28 ]
Total (95% CI) 54 54 100.0 % 0.64 [ 0.10, 4.10 ]
Total events: 5 (Antioxidants), 10 (Control)
Heterogeneity: Tau2 = 1.47; Chi2 = 4.43, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Antioxidant versus control intervention, Outcome 9 Vitamin C levels (mg/dL)-
parallel trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 9 Vitamin C levels (mg/dL) parallel trials







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bhardwaj 2009 62 2.08 (0.82) 38 1.19 (0.54) 37.6 % 1.21 [ 0.78, 1.65 ]
Jarosz 2010 32 0.44 (0.21) 35 0.14 (0.05) 29.2 % 1.98 [ 1.39, 2.58 ]
Siriwardena 2012 33 8.34 (8.76) 37 -0.7 (5.15) 33.1 % 1.26 [ 0.75, 1.78 ]
Total (95% CI) 127 110 100.0 % 1.46 [ 1.00, 1.91 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 4.69, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 6.30 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Antioxidant versus control intervention, Outcome 10 Vitamin C levels
(mg/dL)-sensitivity analysis of parallel and cross-over trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 10 Vitamin C levels (mg/dL) sensitivity analysis of parallel and cross-over trials







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bhardwaj 2009 62 2.08 (0.82) 38 1.19 (0.54) 18.6 % 1.21 [ 0.78, 1.65 ]
Bilton 1994a 20 0.91 (0.39) 20 0.74 (0.38) 16.3 % 0.43 [ -0.20, 1.06 ]
Bilton 1994b 14 0.69 (0.35) 14 0.76 (0.71) 15.0 % -0.12 [ -0.86, 0.62 ]
Jarosz 2010 32 0.44 (0.21) 35 0.14 (0.05) 16.8 % 1.98 [ 1.39, 2.58 ]
Kirk 2006 19 0.45 (0.13) 19 0.32 (0.1) 15.6 % 1.10 [ 0.41, 1.78 ]
Siriwardena 2012 33 8.34 (8.76) 37 -0.7 (5.15) 17.7 % 1.26 [ 0.75, 1.78 ]
Total (95% CI) 180 163 100.0 % 1.01 [ 0.48, 1.53 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 23.98, df = 5 (P = 0.00022); I2 =79%
Test for overall effect: Z = 3.77 (P = 0.00016)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Antioxidant versus control intervention, Outcome 11 Vitamin E levels
(mg/dL)-parallel trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 11 Vitamin E levels (mg/dL) parallel trials







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bhardwaj 2009 62 1.44 (0.65) 38 0.81 (0.24) 34.6 % 1.17 [ 0.74, 1.61 ]
Jarosz 2010 32 0.47 (0.16) 35 0.21 (0.05) 31.5 % 2.21 [ 1.60, 2.83 ]
Siriwardena 2012 33 7.42 (17.95) 37 -1.88 (10.02) 33.9 % 0.64 [ 0.16, 1.12 ]
Total (95% CI) 127 110 100.0 % 1.32 [ 0.51, 2.13 ]
Heterogeneity: Tau2 = 0.45; Chi2 = 15.51, df = 2 (P = 0.00043); I2 =87%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Antioxidant versus control intervention, Outcome 12 Vitamin E levels
(mg/dL)-sensitivity analysis of parallel and cross-over trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 12 Vitamin E levels (mg/dL) sensitivity analysis of parallel and cross-over trials







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bhardwaj 2009 62 1.44 (0.65) 38 0.81 (0.24) 15.5 % 1.17 [ 0.74, 1.61 ]
Bilton 1994a 20 0.91 (0.39) 20 1 (0.42) 14.5 % -0.22 [ -0.84, 0.40 ]
Bilton 1994b 14 1.1 (0.31) 14 1 (0.27) 13.7 % 0.33 [ -0.41, 1.08 ]
Jarosz 2010 32 0.47 (0.16) 35 0.21 (0.05) 14.5 % 2.21 [ 1.60, 2.83 ]
Kirk 2006 19 1.75 (0.23) 19 1.29 (0.09) 12.8 % 2.58 [ 1.70, 3.46 ]
Siriwardena 2012 33 7.42 (17.95) 37 -1.88 (10.02) 15.2 % 0.64 [ 0.16, 1.12 ]
Uden 1990 19 2 (0.77) 19 1.1 (0.57) 13.9 % 1.30 [ 0.59, 2.01 ]
Total (95% CI) 199 182 100.0 % 1.12 [ 0.47, 1.78 ]
Heterogeneity: Tau2 = 0.67; Chi2 = 48.20, df = 6 (P<0.00001); I2 =88%
Test for overall effect: Z = 3.37 (P = 0.00076)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Antioxidant versus control intervention, Outcome 13 Selenium levels (µg/dL)-
sensitivity analysis of parallel and cross-over trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 13 Selenium levels ( g/dL) sensitivity analysis of parallel and cross-over trials





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bilton 1994a 20 8.4 (6) 20 8.5 (7.4) 21.5 % -0.10 [ -4.28, 4.08 ]
Bilton 1994b 14 11.2 (8.5) 14 5.6 (4.8) 21.1 % 5.60 [ 0.49, 10.71 ]
Kirk 2006 19 28.5 (7.5) 19 12.4 (2.7) 21.7 % 16.10 [ 12.52, 19.68 ]
Siriwardena 2012 33 42.73 (32.27) 37 0.92 (12.39) 17.2 % 41.81 [ 30.10, 53.52 ]
Uden 1990 19 18.8 (21.8) 19 4.2 (4.5) 18.4 % 14.60 [ 4.59, 24.61 ]
Total (95% CI) 105 109 100.0 % 14.55 [ 4.38, 24.71 ]
Heterogeneity: Tau2 = 120.36; Chi2 = 65.60, df = 4 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Antioxidant versus control intervention, Outcome 14 β-Carotene levels
(µg/dL)-sensitivity analysis of parallel and cross-over trials.
Review: Antioxidants for pain in chronic pancreatitis
Comparison: 1 Antioxidant versus control intervention
Outcome: 14 -Carotene levels ( g/dL) sensitivity analysis of parallel and cross-over trials







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bilton 1994a 20 98 (22) 20 94 (26) 20.9 % 0.16 [ -0.46, 0.78 ]
Bilton 1994b 14 100 (16) 14 79 (20) 19.9 % 1.13 [ 0.32, 1.93 ]
Kirk 2006 19 112 (8.7) 19 81 (5.5) 17.4 % 4.17 [ 2.99, 5.35 ]
Siriwardena 2012 33 62.56 (125.68) 37 7.85 (34.05) 21.6 % 0.60 [ 0.12, 1.08 ]
Uden 1990 19 110 (16) 19 83 (15) 20.2 % 1.70 [ 0.95, 2.46 ]
Total (95% CI) 105 109 100.0 % 1.46 [ 0.44, 2.48 ]
Heterogeneity: Tau2 = 1.19; Chi2 = 40.92, df = 4 (P<0.00001); I2 =90%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours antioxidants
A D D I T I O N A L T A B L E S
























Banks 1997 X - X X - - X -
Bhardwaj
2009
- X - - - X - -
Bilton
1994a
X - - - X - - -
Bilton
1994b
X - - - X - - -
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Table 1. Pain outcome measures (Continued)
Deprez
2003




X - - - - - - -
Jarosz 2010 - X - - - - - -
Kirk 2006 X - - - - - - X
Nandi 2002 - - X - - X - -
Salim 1991 - - - - - - - -
Siriwardena
2012
X X - - X - - -
Uden 1990 X - - - X - X -












































C 16 13 42 (31-
51)1
8 (62) All par-
ticipants
with CP













































C 30 20 45 (14) 11 (55) CP and
ARP
7.2 (4.1) 2 (10) NA 8 (40) NA
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Table 2. Baseline characteristics of included trials (Continued)
Bilton
1994b
C 14 8 NA NA NA NA NA NA NA NA
Deprez
2003
C 30 NA NA NA All par-
ticipants
with CP



















1 to 3 0 (0) NA NA VAS: 5.5
( SD 0.
56) vs 5.





















C 36 19 NA 13 (68) Non-
gallstone
CP
NA NA NA NA NA
Nandi
2002
P 25 NA NA NA All par-
ticipants
with CP
NA NA NA NA NA
Salim
1991***





























































C 23 20 NA NA Non-
gallstone
CP
NA 7 (35) NA NA NA
All data presented as all participants (antioxidant group vs control group), unless otherwise specified.
Abbreviations:
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VAS: visual analogue scale.
1Median (range).
2Mean (range).
3This is a 3-arm trial. Data are presented in the following order: allopurinol vs dimethylsulfoxide vs control.
Table 3. Effects of antioxidants on chronic pain in chronic pancreatitis
Study Outcome measure(s) Results (antioxidants vs control)
Banks 1997 • VAS score (0-100): difference
in mean decrease from baseline
• McGill score (0-45):
difference in mean decrease
• 2.8, P value 0.24
• -0.3, P value 0.75
Bhardwaj 2009 • Pain-free days/mo: decrease
from baseline
• Pain-free days/mo: after
intervention
• Pain-free participants
• 7.37 (6.75) vs 3.21 (3.99), P
value < 0.001
• 1.68 (2.80) vs 3.36 (4.35), P
value 0.012
• 23/71 (32%) vs 7/56 (13%),
P value 0.009
Bilton 1994a VAS, descriptive pain score No differences (no data shown)
Bilton 1994b VAS, descriptive pain score No differences (no data shown)
Deprez 2003 • Pain VAS score
• Number of participants with
pain
• Not reported
• Only 1 participant with pain
at end of study
Durgaprasad 2005 VAS score (after intervention)
(mean (SE))
5.81 (0.74) vs 6.57 (0.74), NS
Jarosz 2010 • Pain-free participants • 22/32 (68%) vs 11/56 (31%)
, P value 0.002
Kirk 2006 • Daily VAS
• SF-36: pain component
(change from baseline)
• Not analysed because of poor
reporting by participants
• +17 points vs -7 points, P
value < 0.05
Nandi 2002 • Pain score (12 points)
• Pain-free days/mo
• 1.25 vs 3.62, NS
• 3.75 vs 4.12, NS
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Table 3. Effects of antioxidants on chronic pain in chronic pancreatitis (Continued)
Siriwardena 2012 • Change in VAS
• Average daily VAS
• Pain-free participants
• -2.33 (SD 2.09) vs -1.97 (SD
2.46), P value 0.509
• 2.93 (SD 1.96) vs 3.05 (SD
1.96), P value 0.808
• 19 (58%) vs 20 (54%), NS
Uden 1990 • VAS
• McGill score
• Descriptive pain score
• 1.01 (Range 0.16 to 4.26) vs
1.88 (Range 0.22 to 5.76), P value
0.10
• No significant differences
• No clear differences
Abbreviations:
NS: not significant.
VAS: visual analogue scale.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
EBM reviews-Cochrane Central Register of Controlled Trials, 2010, 1st Quarter
1. exp Pancreatitis, Chronic/
2. exp Pancreatitis, Alcoholic/
3. (pancrea$ adj2 chronic$).mp.
4. (Alcohol$ adj2 pancrea$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
5. (pancrea$ adj2 recurren$).mp.
6. or/1-5
7. exp Free Radicals/ag, ai, ip [Agonists, Antagonists & Inhibitors, Isolation & Purification]
8. exp Antioxidants/
9. exp ascorbic acid/ or exp bilirubin/ or exp butylated hydroxyanisole/ or exp butylated hydroxytoluene/ or exp canthaxanthin/ or
exp carotenoids/ or exp catalase/ or exp ergothioneine/ or exp grape seed extract/ or exp melatonin/ or exp nordihydroguaiaretic acid/
or exp probucol/ or exp propyl gallate/ or exp pyrogallol/ or exp quercetin/ or exp selenium/ or exp silymarin/ or exp thioctic acid/ or
exp tocopherols/ or exp tocotrienols/ or exp uric acid/ or exp vitamin e/ or exp alpha-tocopherol/ or exp beta-tocopherol/ or exp
gamma-tocopherol/ or exp zeta carotene/ or exp beta-carotene/ or exp curcumin/ or exp methionine/ or exp allopurinol/
10. exp Oxidants/
11. exp Oxidation-Reduction/
12. *Reactive Oxygen Species/ai [Antagonists & Inhibitors]
13. exp Free Radical Scavengers/
14. exp Peroxides/ai [Antagonists & Inhibitors]
15. antioxidant$.mp.
16. or/7-15
17. 6 and 16
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Appendix 2. MEDLINE search strategy
Ovid MEDLINE(R) 1950 to March Week 4 2010
1. exp Pancreatitis, Chronic/
2. exp Pancreatitis, Alcoholic/
3. (pancrea$ adj2 chronic$).mp.
4. (Alcohol$ adj2 pancrea$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
5. (pancrea$ adj2 recurren$).mp.
6. or/1-5
7. exp Free Radicals/ag, ai, ip [Agonists, Antagonists & Inhibitors, Isolation & Purification]
8. exp Antioxidants/
9. exp ascorbic acid/ or exp bilirubin/ or exp butylated hydroxyanisole/ or exp butylated hydroxytoluene/ or exp canthaxanthin/ or
exp carotenoids/ or exp catalase/ or exp ergothioneine/ or exp grape seed extract/ or exp melatonin/ or exp nordihydroguaiaretic acid/
or exp probucol/ or exp propyl gallate/ or exp pyrogallol/ or exp quercetin/ or exp selenium/ or exp silymarin/ or exp thioctic acid/ or
exp tocopherols/ or exp tocotrienols/ or exp uric acid/ or exp vitamin e/ or exp alpha-tocopherol/ or exp beta-tocopherol/ or exp
gamma-tocopherol/ or exp zeta carotene/ or exp beta-carotene/ or exp curcumin/ or exp methionine/ or exp allopurinol/
10. exp Oxidants/
11. exp Oxidation-Reduction/
12. *Reactive Oxygen Species/ai [Antagonists & Inhibitors]
13. exp Free Radical Scavengers/
14. exp Peroxides/ai [Antagonists & Inhibitors]
15. antioxidant$.mp.
16. or/7-15
17. 6 and 16
18. randomized controlled trial.pt.








27. exp animals/ not humans.sh.
28. 26 not 27
29. 17 and 28
Appendix 3. EMBASE search strategy
EMBASE 1980 to 2010 Week 12
1. exp alcoholic pancreatitis/
2. exp chronic pancreatitis/
3. (pancrea$ adj2 chronic$).mp.
4. (Alcohol$ adj2 pancrea$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
5. (pancrea$ adj2 recurren$).mp.
6. or/1-5
7. exp antioxidant/
8. exp ascorbic acid/ or exp bilirubin/ or exp butylated hydroxyanisole/ or exp butylated hydroxytoluene/ or exp canthaxanthin/ or
exp carotenoids/ or exp catalase/ or exp ergothioneine/ or exp grape seed extract/ or exp melatonin/ or exp nordihydroguaiaretic acid/
or exp probucol/ or exp propyl gallate/ or exp pyrogallol/ or exp quercetin/ or exp selenium/ or exp silymarin/ or exp thioctic acid/ or
exp tocopherols/ or exp tocotrienols/ or exp uric acid/ or exp vitamin e/ or exp alpha-tocopherol/ or exp beta-tocopherol/ or exp
gamma-tocopherol/ or exp zeta carotene/ or exp beta-carotene/ or exp curcumin/ or exp methionine/ or exp allopurinol/
9. exp oxidizing agent/
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10. exp oxidation reduction reaction/
11. exp antioxidant activity/
12. exp oxidation reduction state/
13. exp Free Radical Scavengers/




17. 6 and 16
18. Clinical trial/












31. (allocated adj2 random).tw.
32. Single blind$.tw.
33. Double blind$.tw.






40. Abstract report/ or letter/
41. or/38-40
42. 37 not 41
43. 17 and 42
Appendix 4. CPCI-S search strategy
Conference Proceedings Citation Index-Science (CPCI-S)-1990 to present
# 13. #12 AND #11
# 12. Topic=(pancreatitis)
# 11. #10 OR #8 OR #6 OR #3 OR #2 OR #1
# 10. #9 AND #4
# 9. Topic=(Isolation or Purification)
# 8. #7 AND #4
# 7. Topic=(Scavenger*)
# 6. #5 AND #4
# 5. Topic=(Agonist* or Antagonist* or Inhibitor*)
# 4. Topic=(Free Radical* or Peroxide*)
# 3. Topic=(Oxidation-Reduction) OR Topic=(Oxidant*)
# 2. Topic=(ascorbic acid or bilirubin or butylated hydroxyanisole or butylated hydroxytoluene or canthaxanthin or carotenoids or
catalase or ergothioneine or grape seed extract or melatonin or nordihydroguaiaretic acid or probucol or propyl gallate or pyrogallol
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or quercetin or selenium or silymarin or thioctic acid or tocopherols or tocotrienols or uric acid or vitamin e or ealpha-tocopherol or
beta-tocopherol or gamma-tocopherol or zeta carotene or beta-carotene or curcumin or methionine or allopurinol)
# 1. Topic=(antioxidant*)
Appendix 5. Plain language definitions
This appendix contains definitions of specialised terms used in this review to make them more accessible for all users.
Ameliorating: to make or become better.
Anticarcinogenic: a substance that can inhibit or prevent the development of cancer.
Autoimmune pancreatitis: a rare form of pancreatitis thought to be caused by an immunological reaction of the body against its own
organs (in this case, the pancreas).
Deleterious: causing harm or damage.
Endocrine pancreatic function: refers to the production of insulin by the pancreas to regulate blood sugar levels.
Epidemiology: science concerning the study of causes and patterns of disease.
Etiology: the cause of a disease.
Exocrine pancreatic function: refers to the production of digestive enzymes of the pancreas.
Lipids: fats.
Macromolecules: very large molecules, usually formed by combinations of many smaller subunits.
Nucleic acids: the building blocks of DNA.
Pancreatic divisum: a congenital anomaly in the anatomy of the ducts of the pancreas in which a single pancreatic duct is not formed,
but rather remains as two distinct ducts.
Parenchyme: the body of an organ, used to mainly to distinguish the functional part of an organ from other structures, such as ducts
and blood vessels within that organ.
Postprandial pain: pain after meals.
Somnolence: drowsiness.
Steatorhoea: the presence of excess fat in faeces.
C O N T R I B U T I O N S O F A U T H O R S
Ahmed Ali U, Jens S, Busch ORC, Keus F, Gooszen HG and Boermeester MA participated in the design of this review and in drafting
of the protocol.
Ahmed Ali U and Jens S performed the search, extracted the data, assessed the studies and drafted the first version of the review.
Ahmed Ali U, Busch ORC, Keus F, van Goor H and Boermeester MA participated in the statistical analysis and in interpretation of
the results.
All review authors co-authored the review and read and approved the final manuscript.
D E C L A R A T I O N S O F I N T E R E S T
Authors have reported no conflicts of interest.
56Antioxidants for pain in chronic pancreatitis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.





D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• A new secondary outcome (number of pancreatitis events) has been included in the review.
• The protocol described under ’Searching for other resources’ that review authors planned to “request additional information from
all authors of included trials on any published, unpublished or ongoing trials, by letter or by e-mail.” This is not included in the review.
• The review authors have included assessment of suitability of cross-over design in the assessment of risk of bias in the review
methods.
• The section on data synthesis has been updated with new methods for dealing with parallel/cross-over/combining parallel and
cross-over trials.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Abdominal Pain [blood; ∗drug therapy; etiology]; Analgesics [therapeutic use]; Antioxidants [adverse effects; ∗therapeutic use]; Ascorbic
Acid [blood]; Chronic Pain [drug therapy; etiology]; Gastrointestinal Diseases [chemically induced]; Headache [chemically induced];
Pain Measurement; Pancreatitis, Chronic [∗complications]; Randomized Controlled Trials as Topic; Vitamin A [blood]; Vitamin E
[blood]; beta Carotene [blood]
MeSH check words
Humans
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